Urgent Notice to All Conference Participants

It has been brought to our attention that EHS Housing has recently been cold calling our speakers offering accommodation for a named Fusion conference. Please note that we have no association with EHS Housing and they are acting on our behalf without our permission. We strongly advise that any calls from EHS Housing are ignored or ended immediately. If you are contacted by EHS Housing, please notify us immediately.

All Fusion registration fees are inclusive of accommodation (for three fixed nights) and reservations are handled internally, entirely by Fusion Conferences. If you have any questions concerning your accommodation, please contact Fusion Conferences directly via admin@fusion-conferences.com.

Latest News:
Follow us

Home > Past Conferences > Antiviral

The registration process for this conference has now closed.

Registration Deadlines

Early bird – expired

Talk Submission – expired

Poster Submission – expired

Last Chance – expired

Antiviral

28 Sep 14 - 01 Oct 14

El Jadida, Morocco

Synopsis

*Thank you to our media partners; the European Society for Virology and the Journal of General Virology.*

The fourth Fusion Moroccan Conference will take place at the Mazagan Beach Resort. Located an hour from Casablanca on the coast in the town of El Jadida, this 240 hectare self-contained resort boasts excellent amenities and has superb security. The four day conference will focus on Antiviral Research with a combination of plenary lectures, invited lectures and contributing talks which will be selected from the open abstract submissions (submissions can be uploaded upon registration). A broad range of topics will be covered focusing on the latest clinical practice, as well as the discovery and development of antiviral agents for the treatment and cure of various infectious agents. 

Key Sessions

  • HIV (Treatment)
  • HIV (Eradication)
  • HBV
  • HCV
  • Respiratory Viruses
  • Vector Borne Viruses
  • Norovirus & Emerging Viruses
  • Herpes Viruses
  • Global Pandemics

Our speakers will discuss the latest developments and cutting edge research and look to address the question “What is next for the industry?” The purpose of this conference is to provide a platform for discussion, collaboration and free exchange of ideas, allowing all participants to present their work either as a talk or in poster form. 

Educational Objectives

The conference will address the following learning objectives:

  1. Update participants on the overall progress in antiviral research
  2. Inform clinicians of their choices in patient treatments with existing licenced antiviral therapies
  3. Describe the pipeline of new compounds in development and their likely impact on patient treatments
  4. Enhance the understanding of participants of the development of resistance to antiviral drugs and the importance of treatment selection and adherence to the correct dosing regimens
  5. Evaluate the unmet needs for antiviral drugs to guide both academic and industry participants in their choice of research topics
  6. Help participants foresee the impact of the latest discoveries in virology on the search for new therapies.

Target Audience

This conference will look to bridge the gap between clinical practise, industry and academia and will actively encourage the participation MDs, clinicians, nurses, clinical lab directors, clinical service planners, academic researchers and pharmaceutical industry representatives.

Confirmed Plenary Speakers

Daria Hazuda
Merck 
Mario Stevenson
University of Miami Health System
Michael Manns
Hannover Medical School 
Guey Chuen (Oscar) Perng
National Cheng Kung University
Brent Korba
Georgetown University
Helga Rubsamen-Schaeff
AiCuris
Yves Benhamou
Hôpital Pitié-Salpêtrière

Confirmed Invited Speakers

Baek Kim
Emory University
Carol Brosgart
Viral Hepatitis Action Coalition, CDC Foundation
Leonid Margolis
Eunice Kennedy Shriver National Institute of Child Health and Human Development
Massimo Levrero
Sapienza Universita' di Roma
Osvaldo (Lalo) Flores
Novira Therapeutics 
Tarik Asselah
University Paris Diderot

Sponsors

Programme

15:00 - 20:00 Sunday 28th September 2014
15:00 - 17:00 Registration & Reception
17:00 - 17:15 Opening Comments
17:15 - 20:00 HCV Session
17:15 - 18:00 Michael P. Manns HEPATITIS C: FROM VIRUS DISCOVERY TO CURE
18:00 - 18:30 Carol L. Brosgart
18:30 - 19:00 Tarik Asselah INTERFERON-FREE TREATMENT WITH DIRECT ACTING ANTIVIRALS FOR HEPATITIS C: PERSPECTIVES FOR HCV ERADICATION
19:00 - 19:30 Michael Miller
19:30 - 20:00 Panel Discussion
20:00 - 00:00 Group Dinner & Free Time
08:30 - 20:15 Monday 29th September 2014
08:30 - 10:00 HIV (Eradication/Treatment) I
08:30 - 09:00 Tariq Rana TARGETING VIF REGULATORY AXIS: DEVELOPING NEW AIDS THERAPIES
09:00 - 09:45 Mario Stevenson
09:45 - 10:00 Carole Devaux IDENTIFICATION OF A SMALL HIV-1 NEUTRALIZING ANTIBODY FRAGMENT MIMICKING THE CXCR4 AND CCR5 SURFACE IN A VIREMIC CONTROLLER
10:00 - 10:30 Refreshments
10:30 - 12:15 HIV (Eradication/Treatment) II
10:30 - 11:15 Daria Hazuda HIV LATENCY DRUG DISCOVERY: OPTIMIZING DRUGS TO INDUCE LATENT HIV EXPRESSION
11:15 - 11:45 Monsef Benkirane
11:45 - 12:15 Baek Kim Vpx CONTRIBUTES TO INSENSITIVITY OF SIV to NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS
12:15 - 12:45 Panel Discussion
12:45 - 17:00 Group Lunch & Free Time
14:00 - 17:00 Group Tour to El Jadida (optional)
17:00 - 19:15 HBV
17:00 - 17:45 Yves Benhamou
17:45 - 18:15 Massimo Levrero CAN WE ELIMINATE OR SILENCE THE CCCDNA AND CURE CHB?
18:15 - 18:45 Lalo Flores
18:45 - 19:15 Panel Discussion
19:15 - 20:15 Joep Lange Entrepreneurship Session
20:15 - 00:00 Group Dinner & Free Time
08:30 - 20:30 Tuesday 30th September 2014
08:30 - 10:15 Herpesviruses
08:30 - 09:15 Helga Rübsamen-Schaeff NOVEL THERAPEUTIC APPROACHES AGAINST HERPESVIRUSES
09:15 - 09:45 Leonid Margolis HERPESVIRUSES: HIV EVIL ASSOCIATES
09:45 - 10:15 Panel Discussion
10:15 - 10:45 Refreshments
10:45 - 12:45 Vector Borne, Norovirus & Emerging Viruses
10:45 - 11:30 Brent Korba NOROVIRUS CONTAINS DIVERSE AND UNIQUE ANTIVIRAL TARGETS
11:30 - 12:15 Oscar Perng
12:15 - 12:45 Panel Discussion
12:45 - 17:00 Group Lunch & Free Time
17:00 - 19:00 Respiratory Viruses
17:00 - 17:45 Kenneth Powell DEVELOPMENT OF NOVEL COMPOUNDS TO TREAT RSV INFECTION
17:45 - 18:00 James Mahony CREATION OF NOVEL ANTIVIRALS FOR RESPIRATORY VIRUSES USING SINGLE DOMAIN ANTIBODIES (mFc) AND PEPTIDE INHIBITORS AS THERAPEUTIC FUSION PROTEINS
18:00 - 18:30 Andrew Easton
18:30 - 19:00 Panel Discussion
19:00 - 19:30 Refreshments
19:30 - 20:15 Special Plenary
19:30 - 20:15 Raymond F. Schinazi Curing HCV: The best is yet to come
20:30 - 23:30 *Gala Night & Group Photo*

Speakers

Plenary Speakers

Invited Speakers

  • Dr. Baek Kim
    Director of Drug Discovery, Emory University
  • Prof. Massimo Levrero
    Professor of Medicine, Sapienza University of Rome
  • President & CSO Lalo Flores
    President & CSO, Novira Therapeutics
  • Dr. Leonid Margolis
    Section Chief, NIH
  • Prof. Dr. Tariq Rana
    Professor and V/C, UCSD School of Medicine

Feedback

Sign In

Your feedback has been received.

Cant see images? See gallery on Flickr